These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 24777708)

  • 1. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
    Elshout M; van der Reis MI; Webers CA; Schouten JS
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1911-20. PubMed ID: 24777708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC; Brown MM; Rapuano S; Boyer D
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.
    van Asten F; Michels CTJ; Hoyng CB; van der Wilt GJ; Klevering BJ; Rovers MM; Grutters JPC
    PLoS One; 2018; 13(5):e0197670. PubMed ID: 29772018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.
    Hernandez L; Lanitis T; Cele C; Toro-Diaz H; Gibson A; Kuznik A
    J Manag Care Spec Pharm; 2018 Jul; 24(7):608-616. PubMed ID: 29952707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
    Vottonen P; Kankaanpää E
    Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
    Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
    Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
    Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW
    Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
    Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
    JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
    Dakin HA; Wordsworth S; Rogers CA; Abangma G; Raftery J; Harding SP; Lotery AJ; Downes SM; Chakravarthy U; Reeves BC;
    BMJ Open; 2014 Jul; 4(7):e005094. PubMed ID: 25079928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.
    Holekamp N; Duff SB; Rajput Y; Garmo V
    J Med Econ; 2020 Mar; 23(3):287-296. PubMed ID: 31502893
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity.
    Butt T; Patel PJ; Tufail A; Rubin GS
    Appl Health Econ Health Policy; 2014 Jun; 12(3):289-97. PubMed ID: 24610632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration.
    Johnston SS; Wilson K; Huang A; Smith D; Varker H; Turpcu A
    Adv Ther; 2013 Dec; 30(12):1111-27. PubMed ID: 24310208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Minimization Analysis of Ranibizumab Versus Aflibercept for Treating Saudi Patients With Visual Impairment Owing to Age-Related Macular Degeneration or Diabetic Macular Edema.
    El-Dahiyat F; Eljilany I
    Value Health Reg Issues; 2020 Sep; 22():23-26. PubMed ID: 32247191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S; Bressler NM
    Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.